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Prevention of Diabetes by FTY720-Mediated Stabilization
of Peri-Islet Tertiary Lymphoid Organs
Cristina Penaranda,1 Qizhi Tang,1,2 Nancy H. Ruddle,3 and Jeffrey A. Bluestone1
OBJECTIVE—The nonobese diabetic (NOD) mouse is a well-
established mouse model of spontaneous type 1 diabetes, which
is characterized by an autoimmune destruction of the insulin-
secreting pancreatic -cells. In this study, we address the role of
tertiary lymphoid organs (TLOs) that form in the pancreas of
NOD mice during disease progression.
METHODS—We developed a model designed to “lock” lympho-
cytes in the pancreatic lymph node (PLN) and pancreas by the
use of FTY720, which blocks the exit of lymphocytes from lymph
nodes. A combination of flow cytometry, immunofluorescence,
and analysis of clinical scores was used to study the effects of
long-term FTY720 treatment on TLO development and develop-
ment of diabetes.
RESULTS—Continuous treatment of NOD mice with FTY720
prevented diabetes development even at a time of significant
insulitis. Treatment withdrawal led to accelerated disease inde-
pendent of the PLN. Interestingly, naive T-cells trafficked to and
proliferated in the TLOs. In addition, morphological changes
were observed that occurred during the development of the
disease. Remarkably, although the infiltrates are not organized
into T/B-cell compartments in 8-week-old mice, by 20 weeks of
age, and in age-matched mice undergoing FTY720 treatment, the
infiltrates showed a high degree of organization. However, in
naturally and FTY720-induced diabetic mice, T/B-cell compart-
mentalization was lost.
CONCLUSION—Our data show that TLOs are established dur-
ing diabetes development and suggest that islet destruction is
due to a loss of TLO integrity, which may be prevented by
FTY720 treatment. Diabetes 59:1461–1468, 2010
The nonobese diabetic (NOD) mouse is a well-established mouse model of spontaneous type 1diabetes, which is characterized by an autoim-mune attack against the insulin-secreting pan-
creatic -cells in the islets (1). Multiple factors play a role
in the development of diabetes in the NOD mouse model
starting with the activation of T-cells by antigen-presenting
cells, leading to T-cell differentiation and, ultimately, de-
struction of the target tissue. However, the location of
these key events remains unclear.
Lymphocytic infiltrates can be detected surrounding the
islets in NOD mice as early as 3–4 weeks of age (2). The
infiltrate continues to amass and by 15–18 weeks of age
completely invades the islet and destroys it. Although
virtually all NOD mice show some level of insulitis, only
60–80% of females and 20–30% of males, depending on the
colony, develop fulminant disease (1). Therefore, the
autoimmune destruction of pancreatic islets in NOD mice
has been suggested to include two phases: insulitis, which
involves infiltration of lymphocytes into the pancreas, and
overt diabetes, which involves killing of the -cells in the
islets and resultant hyperglycemia (3). Interestingly, it has
been shown that removal of the draining pancreatic lymph
node at 3 weeks of age protects from disease development
but removal at 10 weeks of age has no effect on disease
development, suggesting that disease can become lymph
node independent (4).
Organized lymphocytic infiltrates forming ectopically in
nonlymphoid tissues have been termed tertiary lymphoid
organs (TLOs) because of their morphological similarities
to secondary lymphoid organs (5). These include the
presence and compartmentalization of T- and B-cells con-
trolled by chemokine gradients, high endothelial venules
(HEVs), lymphatic vessels, and antigen-presenting cells.
TLOs have been described in a variety of autoimmune
diseases including gastritis, thyroiditis, and systemic lupus
erythematosus (5). However, a detailed analysis of TLOs in
the pancreas of NOD mice has not been performed and
could provide insights into the development of the disease,
including whether antigen presentation occurs in the
pancreas leading to epitope spreading and expansion of
the immune response; whether continuous recruitment of
lymphocytes to the site is necessary to cause disease; and
whether priming of T-cells in these structures sufficiently
activates them to become pathogenic. In this study, we
used the S1P1 agonist FTY720, which blocks T-cell egress
from lymphoid tissues (6), to “lock” cells in the draining
pancreatic lymph node and the pancreas to study the role
of TLOs in the pathogenesis of diabetes in NOD mice.
RESEARCH DESIGN AND METHODS
Mice. NOD, NOD.BDC25 (7), and NOD.Rag2 knockout mice were bred at the
University of California, San Francisco. NOD mice were also purchased from
Taconic. All mice were housed under specific pathogen–free conditions at the
University of California, San Francisco Animal Barrier Facility. All animal
experiments were approved by the Institutional Animal Care and Use Com-
mittee of the University of California, San Francisco. For diabetes incidence,
urine glucose was followed twice weekly.
Human pancreas samples. Samples from human diabetic patients were
obtained through the Network for Pancreatic Organ Donors with Diabetes
(nPOD) project of the Juvenile Diabetes Research Foundation (JDRF). The
age of the patients ranged from 12 to 22 years old and they were diagnosed
with type 1 diabetes 1–8 years prior to death. Details regarding their collection
and methods of preparation can be found at http://www.jdrfnpod.org.
FTY720 administration. FTY720 was obtained from Novartis Pharmaceuti-
cals and was dissolved in normal saline. A dose of 20 g/day was administered
by intraperitoneal injection three times per week.
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Pancreatic lymphadenectomy. Pancreatic lymph nodes were removed as
previously described (4).
Reagents. For flow cytometry, labeled antibodies specific for CD4 clone RM4–5,
CD8 clone 53–6.7, CD25 clone PC61, FoxP3 clone FJK-16s, CD45 clone I3/2.3,
CD11c clone N418, CD86 cone GL1, CD40 clone 3/23, CD80 clone 16–10A1, and
I-Ag7clone 10.2.16 were used. Cells were fixed and permeabilized using Foxp3
Staining Kit per manufacturer’s protocol (ebiosciences, San Diego, CA). For
immunofluorescence, primary antibodies specific for mCD4 clone L3T4, hCD4
clone RPA-T4, mCD45R/B220-biotin clone RA3.6B2, hCD19 clone H1B19, mCD31
clone 390, murine mucosal addressin cell adhesion molecule (mMAdCAM) clone
MECA367, murine lymphatic vessel endothelial hyaluronan receptor-1 (mLyve-1)
clone 223322, and murine fibroblast specific clone ERTR7 were used. MECA79
antibody specific for peripheral node addressin (PNAd) was obtained from Dr.
Steve Rosen (University of California, San Francisco).
Immunofluorescence. Pancreata were isolated and frozen in optimum cutting
temperature embedding compound. Consecutive sections (7 m) were cut with a
Leica CM 3050S cryomicrotome and fixed for 15 min in acetone at 20°C.
Sections were blocked with 5% BSA and 3% normal serum corresponding to the
secondary antibody and/or Avidin/Biotin Blocking Kit per manufacturer’s proto-
col (Vector, Burlingame, CA). Slides were incubated with primary and secondary
antibodies for 1–2 h at room temperature and counterstained with Gill hematox-
ylin. Digital images were captured with an Optiphot microscope equipped with an
Axiocam digital camera and analyzed using Adobe Illustrator CS2.
Isolation of lymphocytes from pancreas. Lymphocytes were isolated from
the pancreas as previously described (8).
Isolation of dendritic cells. Dendritic cells were isolated from lymph nodes
and islets as previously described (9).
Adoptive transfer and CFSE dilution analysis. CD4CD25CD62L cells
were sorted from NOD.BDC2.5TgThy1.1 mice. Cells were then labeled with
carboxyfluorescein succinimidyl ester (CFSE) and 1  106 transferred to
NOD.Thy1.2 mice. Immediately after transfer and daily until time of harvest,
mice were injected with FTY720. On day 5, single-cell suspensions from
pancreas, spleen, pancreatic lymph node (PLN), and inguinal lymph nodes
(ILN) were stained for flow cytometric analysis. To calculate the percentage
of T-cells that entered cell cycle, the original number of cells that entered cell
cycle was determined by dividing the number of events at each division (i.e.,
CFSE peak) by the number of divisions that occurred. This number was
divided by the total number of cells (original number of cells that entered cell
cycle  number of cells that never entered cell cycle).
Statistical analysis. The statistical significance between Kaplan-Meier sur-
vival curves in Figs. 1 and 4 was determined by a log-rank test using Prism
software. The statistical significance of differences between groups in Table 1
and Fig. 3 was determined by two-tailed Student t test using Excel. The
statistical significance of differences between groups in supplementary Fig. 2
(available in an online appendix at http://diabetes.diabetesjournals.org/
content/early/2010/03/10/db09-1129/suppl/DC1) was determined by the Mann-
Whitney test using Prism software.
RESULTS
Continuous FTY720 treatment prevents diabetes but
leads to rapid disease development upon withdrawal.
FTY720 blocks T-cell egress from lymph nodes and has
been shown to be effective clinically in the treatment of
autoimmunity and transplant rejection (10). We set up a
model using FTY720 that was designed to examine the
effects of “locking” lymphocytes in the PLN and pancreas.
Treatment of female NOD mice with 20 g/day 3 times per
week starting at 10 or 14 weeks of age, when insulitis had
already begun or was established, completely protected
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FIG. 1. FTY720 treatment of NOD mice. A: Female NOD mice treated three times per week with 20 g/day FTY720 from 12 to 22 weeks of age
(shaded). Control n 25; FTY720 treated n 10. P 0.0091 after FTY720 withdrawal. B: Female NOD mice treated as in (A) starting at 14 weeks
of age for 7 weeks. Control n  20; FTY720 treated n  8. P  0.0004 after FTY720 withdrawal. C: Female NOD mice treated as in (A) starting
at 7 weeks of age for 9 weeks (shaded). Control n  10; FTY720 treated n  15 pooled from two independent experiments. P  0.7723 after
FTY720 withdrawal. D: Histological analysis of pancreas sections at the end of FTY720 treatment in panel (A). Ten weeks untreated n  6 mice,
1,001 individual islets; 20 weeks untreated n  6 mice, 576 individual islets; 20 weeks FTY720 treated n  7 mice from two independent
treatments, 816 individual islets. Grade 0  no infiltrate. Grade 1  <25% of islet infiltrated. Grade 2  25–75% of islet infiltrated. Grade 3 
>75% of islet infiltrated.
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mice from diabetes development (Fig. 1A and B). With-
drawal of drug treatment after 10 or 7 weeks, respectively,
led to rapid development of diabetes. Of mice, 70–88%
were diabetic 18 days after treatment withdrawal in mul-
tiple independent experiments (Fig. 1A and B). This com-
pares with 48% incidence among untreated control mice.
Similarly, continuous treatment until 25 weeks led to
protection during treatment and acceleration of disease
upon withdrawal (data now shown). To assess whether
insulitis at the beginning of treatment was necessary for
the rapid disease onset seen after withdrawal, we began
treatment at 7 weeks of age, when insulitis was present but
minimal (Fig. 1C). Unlike the previous regimens, with-
drawal 10 weeks later did not lead to rapid diabetes
development. By 29 weeks of age, 12 weeks after FTY720
withdrawal, only 50% of FTY720-treated mice had become
diabetic with similar kinetics as observed in control mice.
As expected, continuous FTY720 treatment led to a
marked decreased of circulating lymphocytes, which re-
turned to normal levels 7 days after treatment withdrawal
(data not shown). These results suggest that the disease
acceleration was not due to direct effects of the drug on
the pancreas.
Continuous FTY720 treatment does not clear pancre-
atic infiltrate. A possible explanation for disease protec-
tion during FTY720 treatment is clearance of pancreatic
infiltrate. Histological analysis and scoring of islet infil-
trates of 20-week-old mice that had been treated with
FTY720 from 10–12 to 20–22 weeks of age and age-
matched controls showed that treatment had limited ef-
fects on islet infiltration (Fig. 1D). Of the islets, 40% had
some degree of peri-islet infiltration similar to that ob-
served in untreated 10- to 12-week-old NOD mice, suggest-
ing that FTY720 treatment did not clear tissue infiltrate but
rather blocked trafficking of new cells from the periphery.
Interestingly, the overall fraction of pancreatic islets ex-
hibiting grades 1, 2, or 3 insulitis remained consistent
between 10- and 20-week-old FTY720-treated mice, sug-
gesting that FTY720 blocked further islet invasion.
FTY720 treatment leads to minor changes in infiltrat-
ing CD4 T-cells. Next, we compared the infiltrate in
20- to 22-week-old mice undergoing continuous FTY720
treatment from 10–12 weeks of age (as in Fig. 1A) to
aged-matched untreated controls. The total number of
cells in the nondraining ILN and the spleen was threefold
less in FTY720-treated mice (Table 1) likely due to seques-
tration of cells in the thymus (data not shown) and
systemic lymphopenia, respectively. Interestingly, the to-
tal cell number in the PLN remained unchanged (Table 1),
a result that could reflect continued expansion of cells
specific for pancreatic antigens. Similar results were ob-
served when examining the CD4 and CD8 T-cells (Table
1). In the pancreas, the percentage of CD4 T-cells de-
creased twofold to threefold, but there was no change in
infiltrating CD8 T-cells (Table 1). These results suggest
that disease protection during treatment, but not the
disease acceleration seen after withdrawal, may be due to
a decrease in infiltrating CD4 T-cells. Importantly, these
data suggest that potentially pathogenic T-cells were able
to persist at the site of inflammation without continuous
trafficking from peripheral lymphoid tissues.
Because FTY720 has been suggested to increase the
proportion of regulatory T cells (Tregs;11,12), we assessed
whether a proportional increase in Tregs could account
for the disease protection during treatment. Analysis of
absolute numbers of Tregs showed that the total number
of CD4Foxp3 cells decreased in the ILN and spleen but
remained the same in the PLN (Table 1). The percentage of
CD4Foxp3 cells in the pancreas remained the same;
however, the absolute number of Tregs likely decreased in
treated mice, suggesting that changes in Tregs were un-
likely to be responsible for disease prevention.
In addition to inhibiting the migration of lymphocytes,
FTY720 has also been suggested to have effects on den-
TABLE 1
Analysis of T-cells during FTY720 treatment
Pancreas PLN ILN Spleen
Total cell number (106)
Control ND 2.73 1.40* 9.97 3.50* 79.6 25.9*
FTY720 treated ND 3.16 0.80 3.65 1.03 31.7 15.2
% CD4 of CD45 cells
Control 26.2 9.6* 48.5 1.5* 51.4 7.5* 28.3 4.7*
FTY720 treated 9.3 1.9 32.4 1.8 27.8 3.3 13.1 2.6
Total CD4 cell number (106)
Control ND 1.32 0.67 4.99 1.47* 21.6 4.48*
FTY720 treated ND 1.02 0.26 1.00 0.25 4.07 1.95
% Foxp3 of CD4 cells
Control 17.3 6.8 21.6 5.7 11.8 2.6* 17.9 4.2
FTY720 treated 26.5 9.8 24.3 3.3 27.2 2.3 20.0 3.1
Total CD4Foxp3 cell number (106)
Control ND 0.28 0.15 0.60 0.23* 3.91 1.33*
FTY720 treated ND 0.25 0.07 0.27 0.07 0.84 0.45
% CD8 of CD45 cells
Control 7.2 5.3 19.8 2.6* 20.5 2.4* 12.5 2.0*
FTY720 treated 4.0 4.1 31.9 3.3 31.5 3.4 4.0  1.0
Total CD8 cell number (106)
Control ND 0.54 0.29* 2.02 0.73* 9.86 3.31*
FTY720 treated ND 1.01 0.28 1.13 0.26 1.25 0.59
NOD female mice were treated for 10 weeks with FTY720 beginning at 10–12 weeks of age. Mice were analyzed on the last day of treatment.
Total cell number and percentages of CD4 and CD8 lymphocytes among CD45 cells and CD4Foxp3 cells among CD4 cells were
determined by flow cytometry. Mean values of 3 independent treatment experiments are shown. Control n  8. FTY720 treated n  11. ND,
not determined. *P  0.01 between control and FTY720 treated in the same tissue.
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dritic cells (DCs;13). To test this hypothesis, we treated 16-
to 18-week-old NOD mice with FTY720 for 10 days and
analyzed the percentage of CD11c cells in the islets,
PLNs, and ILNs as well as their expression of CD86, CD40,
CD80, and I-Ag7 (major histocompatibility complex class
II). The treatment did not affect the percentage of DCs or
their maturation state in any tissue analyzed (supplemen-
tary Fig. 1), suggesting that disease protection observed
during FTY720 treatment or disease acceleration observed
after treatment withdrawal was not due to changes in DCs.
Analysis of tertiary lymphoid organs in the pancreas.
Because the total cell number in the PLN was unaffected
by FTY720 treatment and a significant number of cells
remained in the pancreas, it was unlikely that disease
protection during FTY720 treatment could be attributed
solely to a reduction in infiltrating cells. Therefore, we
analyzed the effect of long-term FTY720 treatment on the
structure and characteristics of TLOs. Because FTY720
blocks lymphocyte egress from the lymph nodes, we
hypothesized that disease was prevented by inhibiting
lymphocyte egress from the TLOs in the pancreas to the
site of tissue destruction—the -cells. First, we character-
ized the TLOs in pre-diabetic 8-week-old, nondiabetic
20-week-old and naturally diabetic mice by immunofluo-
rescent staining of individual markers on consecutive
pancreas sections using markers described in the “Re-
search Design and Methods” section.
ERTR7 reactivity and CD31 vessels were observed
surrounding all islets and throughout the acinar tissue at
all time points analyzed (Fig. 2A and data not shown). In
addition, ERTR7 reactivity was found within the infiltrate,
suggesting that these structures have a supporting stromal
network, as is seen in T-cell zones in the spleen and lymph
nodes (14). However, although the results trend toward an
increase in the association of the presence of MAdCAM
or Lyve vessels and disease progression, these differ-
ences were not statistically significant (supplementary Fig.
2B). In addition, most infiltrates in both pre-diabetic and
naturally diabetic mice contained PNAd HEVs (Fig. 2D–
G), suggesting that, like secondary lymphoid organs, these
structures are capable of recruiting naive T-cells. Analysis
of at least three consecutive sections showed that infil-
trates of pre-diabetic 20-week-old mice were usually, but
not always, associated with insulin-producing islets (Fig.
2A and E). Although T- and B-cells were present in the
pancreas of 8-week-old mice, only 15% (3/20) of infiltrates
showed clear compartmentalization, whereas 89% (24/27)
of infiltrates in 20-week-old mice showed distinct T- and
B-cell zones. In the majority of these, the T-cell zone was
closer to the islet, whereas the B-cell zone was on the edge
of the infiltrate, reminiscent of lymph nodes (Fig. 2A).
Only 15% of infiltrates (3/19) in naturally diabetic mice
showed T/B-cell compartmentalization, which correlated
with an absence of insulin-positive islets that we attribute
to destroyed -cells (Fig. 2B and G). However, -cells may
have been present but not producing insulin because of
inflammation (15). True TLOs, defined as infiltrates with
T/B compartmentalization and association with at least
two of the vascular markers analyzed, were present in 15%
(3/20) of infiltrates in 8-week-old mice, increasing to 81%
(22/27) of infiltrates in 20-week-old mice but decreasing to
only 26% (5/19) of infiltrates in naturally diabetic mice
(Fig. 2D–F). Therefore, TLOs peaked as a proportion of
the infiltrate at the “peak” of the inflammatory response
before diabetes onset.
We analyzed NOD.Rag2 knockout mice to assess
whether the appearance of TLO markers was due to
inflammation or a normal characteristic of the NOD pan-
creas (Fig. 2C). As in NOD mice, there was ERTR7
reactivity and CD31 vessels around islets and throughout
the acinar tissue. MAdCAM and Lyve-1 vessels were
associated with 30 and 59% of islets, respectively, which is
significantly lower than in mice with an intact immune
system (supplementary Fig. 2B). There was no PNAd
staining, suggesting an adaptive immune response was
necessary for the development of HEVs in the pancreas
(data not shown).
Analysis of FTY720-treated mice after 8–10 weeks of
continuous treatment (20 weeks old) showed that the
majority of the infiltration was associated with insulin-
producing islets (Fig. 2G). Moreover, the infiltrates in
FTY720-treated mice showed a similar degree of organiza-
tion, based on T/B compartmentalization (19/21), as age-
matched untreated controls (Fig. 2G). Similar to pre-
diabetic and naturally diabetic mice, the TLOs in these
mice had PNAd HEVs as well as Lyve-1 and MAdCAM
vessels (supplementary Fig. 2A). Analysis of mice on day
12 after FTY720 release, when 30–60% mice have become
diabetic, showed that the infiltrates lose T/B compartmen-
talization and are similar to those of naturally diabetic
mice; only 31% (5/16) of infiltrates were true TLOs based
on our criteria (Fig. 2H).
In an attempt to define TLOs in humans with type 1
diabetes, we analyzed pancreatic sections from four such
patients obtained through JDRF’s nPOD program (http://
www.jdrfnpod.org). Although CD4 T-cells and CD19
B-cells were found surrounding insulin islets (supple-
mentary Fig. 3), the cells were scattered and did not form
large clusters as was observed in pre-diabetic and early-
onset diabetic NOD mice. However, at present, we cannot
distinguish whether the absence of TLOs in the human
samples is due to temporal differences in sampling (i.e.,
the human tissues represented those obtained from indi-
viduals with longer disease duration than those we ana-
lyzed in NOD mice) or actual differences between the
disease in the two species.
Accelerated disease upon FTY720 withdrawal is in-
dependent of the draining pancreatic lymph node. A
possible explanation for the accelerated disease after
cessation of FTY720 is that the relevant antigen-specific
cells continue to expand to sufficient numbers and activa-
tion status to cause rapid disease upon treatment with-
drawal and restoration of trafficking. This would suggest
that during long-term FTY720 treatment there are reser-
voirs of islet-reactive cells that accumulate either within or
outside of the pancreas. To determine in which lymphoid
tissues islet antigens are presented that can lead to anti-
gen-specific T-cell expansion, we transferred 1  106
CFSE-labeled naive CD4CD25CD62L islet antigen–
specific BDC2.5 TCR-Tg cells to 8-week-old NOD mice and
treated them with FTY720 daily to prevent recirculation.
After 5 days, cells were harvested and proliferation was
evaluated by CFSE dilution (Fig. 3). In control treated
mice, 37 and 50% of transferred cells had entered the cell
cycle in the PLN and the pancreas, respectively. The
proliferation was antigen dependent, as only 8 and 14% of
the TCR-Tg T-cells went into cycle in the ILN and spleen,
respectively. In FTY720-treated mice, a higher percentage
of cells that entered the cell cycle were observed in the
PLN (54%) and pancreas (75%). These results suggested
that naive cells were able to home directly to and prolif-
erate in the pancreas and that FTY720 treatment did not
DIABETES PREVENTION BY TLO STABILIZATION
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prevent antigen presentation or antigen-driven prolifera-
tion. Similar to untreated mice, 6 and 2% of the cells in the
ILN and spleen, respectively, proliferated in FTY720-
treated mice, suggesting that the PLN is the only second-
ary lymphoid tissue where islet antigens are presented and
that the proliferating cells seen in the spleens of untreated
mice are a result of recirculation.
We reasoned that the cells causing rapid onset of
diabetes upon FTY720 withdrawal originated from either
the PLN or the pancreas. Thus, we tested the effect of
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indicates a separate mouse. Bar represents 100 m. *Infiltrates considered to be true TLOs based on T/B compartmentalization and association
with at least two of the vascular markers analyzed. (A high-quality digital representation of this figure is available in the online issue).
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surgical removal of the PLN in mice undergoing FTY720
treatment. FTY720 treatment was begun at 12 weeks of
age, the PLN was surgically removed (PLNx) 9 weeks
later, and treatment was withdrawn 1 week after the
surgery. Of mice that underwent PLNx, 40% developed
diabetes within 15 days of treatment withdrawal compared
with 80% of sham controls (Fig. 4A). As our previous
experiments had shown, age at beginning of treatment
influences whether there is accelerated disease upon
treatment withdrawal, suggesting that although the PLN
may be important early in disease progression, the require-
ment of this lymph node diminishes as disease progresses.
We hypothesized that if we began treatment late in life, a
greater percentage of mice would develop disease inde-
pendently of the PLN because of the increased level of
infiltration at the time of treatment. Therefore, for the
second series of experiments, we began treatment at 16
weeks of age, removed the PLN at 23 weeks of age, and
withdrew FTY720 1 week later. Under these conditions,
50% of sham control mice and 65% of mice that underwent
PLNx became diabetic within 15 days of FTY720 with-
drawal (Fig. 4B). These results suggest that the diabetes
acceleration observed after FTY720 can be attributed to
antigen-reactive T-cells present in both pools. However,
the PLN is not required for the accelerated disease in mice
with the most progressed disease. In this setting, the cells
present in the TLOs of the pancreas at the beginning of the
treatment are sufficient to cause diabetes upon FTY270
withdrawal.
DISCUSSION
In this study, we used FTY720 treatment of NOD mice to
prevent trafficking of lymphocytes into the pancreas and
studied the role of TLOs in diabetes development. Our
results show that continuous FTY720 treatment prevents
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FIG. 3. Proliferation of BDC2.5 Tg T-cells in NOD mice. CD25CD62L naive BDC2.5 TCR transgenic cells (1  106) were CFSE labeled and
transferred to 8- to 10-week-old NOD females. After transfer, mice were treated with 20 g FTY720 daily. On day 5, BDC2.5 proliferation was
analyzed by CFSE dilution in the pancreas, draining PLN, nondraining ILN, and spleen. A: Representative histograms of control (top) and
FTY720-treated (bottom) mice. B: Percentage of cells that entered the cell cycle was calculated as described in the “Research Design and
Methods” section. Data were pooled from two independent experiments. *P < 0.01.
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diabetes development and, when withdrawn, leads to an
accelerated disease that is independent of the PLN if
treatment is begun when insulitis is established. Analysis
of NOD mice at various stages of disease and during
FTY720 treatment showed that lymphocyte infiltration into
the pancreas leads to the formation of organized TLOs
characterized by T/B compartmentalization and special-
ized vasculature, including lymphatic vessels, HEVs, and
MAdCAM-expressing vessels. Furthermore, our data
showed that these structures do not exhibit T/B compart-
mentalization in naturally diabetic mice even though the
specialized vasculature remains unchanged. We propose a
model where cells that infiltrate the pancreas organize into
TLOs that, like secondary lymphoid organs, have T/B
compartmentalization and specialized vasculature. Once
these structures are established, the immune response is
amplified and eventually is sufficient to destroy the neigh-
boring islet. In doing so, T/B compartmentalization is lost
and TLO integrity is lost.
Although there is agreement that the main mode of
action of FTY720 is by blocking lymphocyte egress from
the thymus and lymph nodes, some controversy remains
concerning other effects on T-cells. Indeed, protection
from disease development even in the presence of signif-
icant infiltration in the pancreas suggested the possibility
of direct effects of FTY720 on T-cells. Previous studies
have suggested that FTY720 induces Tregs or enhances
their function (11,12). In our study, increased Tregs were
observed only in the ILN, not in the PLN or in the
pancreas, the locations where an increase in Tregs would
be likely to have an effect on disease outcome. Interest-
ingly, it is unclear whether this increase was due to
preferential homing, proliferation, or conversion from
effectors to Tregs. FTY720 has also been suggested to
induce apoptosis of T-cells (10). Similar to our results,
Maki et al. reported that continuous treatment of NOD
mice with FTY720 prevented diabetes development during
treatment (16). They observed diabetes protection even
after withdrawal in mice that started treatment at 4 weeks
of age, which led to the suggestion that therapy eliminated
autoreactive effector T-cells by FTY720-mediated apopto-
sis (16). Rather than previous interpretations, we propose
that the lack of accelerated disease after treatment of
young pre-diabetic NOD mice is a result of a low number
of antigen-specific T-cells in TLOs at the time of treatment
initiation, which was not sufficient to develop a pathogenic
T-cell population capable of rapid disease induction
once drug treatment was discontinued. This interpreta-
tion fits with the analysis of 8-week-old mice, where
TLOs were not yet organized into distinct T- and B-cells
zones and therefore not fully established by this point.
Moreover, in a model of allograft rejection, Habicht et
al. showed that FTY720 treatment had no effect either
alloreactive T-cell apoptosis or T-cell activation, prolif-
eration, and cytokine production (17). Our data are
consistent with the documented mechanism of action of
FTY720, namely, that FTY720 controls exit from primary
and secondary lymphoid organs. In addition, our data
suggest that FTY720 also controls exit out of TLOs and
entry into the neighboring pancreatic tissue, thereby
stabilizing these structures and preventing islet destruc-
tion and diabetes development.
Tertiary lymphoid organs have been previously de-
scribed in the pancreas of NOD mice; however, a
characterization at different stages of disease including
association with specialized vessels had not been de-
scribed. Our data show that Lyve-1 and MAdCAM
vessels are present even in noninflammatory conditions,
such as the pancreas of NOD.Rag2 knockout mice. Inflam-
mation in NOD mice results in a higher percentage of islets
associated with specialized vasculature. Whether this in-
crease reflects neovascularization or expression of these
markers on vessels that were previously present is not
known.
The role of TLOs in the amplification of the immune
response is unclear (18). Our results expand on the role of
TLOs in T-cell responses. The adoptive transfer of naive
BDC2.5 Tg T-cells during FTY720 treatment shows that
naive cells can in fact be recruited directly to the pancreas
rather than having to be primed first in the PLN. In
addition, proliferation of these cells in the pancreas sug-
gests that there is local antigen presentation (19). How-
ever, it is not known how the antigen reaches the TLOs. It
is possible that islet-resident dendritic cells traffic to the
TLO bringing antigen with them; that antigen is picked up
by TLO resident antigen-presenting cells, such as macro-
phages and DCs, at the TLO/islet boundary; or that antigen
travels through the lymph from the islet to the TLO.
The requirement of the lymphotoxin axis on TLO devel-
opment has been explored because of its importance in
lymph node development. Disruption of TLOs by overex-
pression of LIGHT, a LTR ligand, in the pancreas of NOD
mice (NOD-RIP-LIGHT) results in accelerated diabetes
compared with nontransgenic controls (20). This suggests
that during the natural course of disease and TLO break-
down, additional signals are present that allow pathogenic
cells to destroy the islets rather than instructing them to
leave the pancreas. Therefore, preventing islet destruction
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FIG. 4. Role of draining PLN on FTY720-induced diabetes. A: NOD
female mice were treated for 9–10 weeks (shaded) with FTY720
beginning at weeks 11–13. During the last week of treatment, the PLNs
were surgically removed. Disease incidence was monitored after
FTY720 withdrawal. Data are pooled from two independent experi-
ments. Sham n  8, PLNx n  9. P  0.0817. B: NOD female mice were
treated for 8 weeks (shaded) with FTY720 beginning at week 16.
During the last week of treatment, the pancreatic lymph nodes were
surgically removed. Disease incidence was monitored after FTY720
withdrawal. Sham n  6, PLNx n  8. P  0.8456.
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by altering TLO maintenance will require a deeper under-
standing of the signals that control islet destruction. In
addition, targeting of TLOs may be difficult because the
same signals that induce, and presumably maintain, TLOs
are also necessary for lymph node integrity (18).
Analysis of TLOs in type 1 diabetic patients has been
challenging. In accordance with our findings, Willcox et al.
analyzed pancreas samples from patients who died within
18 months of diagnosis (21) and found scattered infiltrat-
ing cells surrounding glucagon- or insulin-positive islets.
We hypothesize that the lack of true TLOs in the nPOD
samples is because of timing: analyzing long-term clini-
cally diabetic patients likely misses the peak of the im-
mune response in the pancreas. In fact, the NOD mouse
data support this interpretation because we found 81% of
infiltrates were localized to TLOs in 20-week-old pre-
diabetic mice but only 26% of infiltrates were localized to
TLOs in diabetic mice. This highlights the need for screen-
ing and analysis of pre-diabetic, autoantibody-positive
individuals to elucidate the role of TLOs in type 1 diabetes.
Promising clinical trials using FTY720 as a treatment for
multiple sclerosis are under way (22), suggesting its pos-
sible use in treating other autoimmune diseases such as
type 1 diabetes. However, our data suggest that autoreac-
tive cells continue to expand during treatment and become
highly pathogenic, such that if treatment were advertently
or inadvertently discontinued the stealth T-cells rapidly
destroy the target tissue. This has not been documented
thus far in the clinical trials; whether the rebound effect is
restricted to diabetes or this mouse model or whether it
requires longer treatment remains to be seen.
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